Xenon Pharmaceuticals Inc.
XENE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $9,434 | $18,437 |
| % Growth | – | -100% | -48.8% | – |
| Cost of Goods Sold | $2,560 | $167,512 | $0 | $0 |
| Gross Profit | -$2,560 | -$167,512 | $9,434 | $18,437 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $210,394 | $167,512 | $105,767 | $75,463 |
| G&A Expenses | $68,904 | $46,542 | $32,810 | $21,967 |
| SG&A Expenses | $68,904 | $46,542 | $32,810 | $21,967 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2,560 | -$167,512 | $0 | $0 |
| Operating Expenses | $276,738 | $46,542 | $138,577 | $97,430 |
| Operating Income | -$279,298 | -$214,054 | -$129,143 | -$78,993 |
| % Margin | – | – | -1,368.9% | -428.4% |
| Other Income/Exp. Net | $40,879 | $31,369 | $3,888 | $105 |
| Pre-Tax Income | -$238,419 | -$182,685 | -$125,255 | -$78,888 |
| Tax Expense | -$4,089 | -$292 | $118 | -$6 |
| Net Income | -$234,330 | -$182,393 | -$125,373 | -$78,882 |
| % Margin | – | – | -1,328.9% | -427.8% |
| EPS | -3.01 | -2.73 | -2.06 | -1.77 |
| % Growth | -10.3% | -32.5% | -16.4% | – |
| EPS Diluted | -3.01 | -2.73 | -2.06 | -1.77 |
| Weighted Avg Shares Out | 77,895 | 66,889 | 60,542 | 43,627 |
| Weighted Avg Shares Out Dil | 77,895 | 66,889 | 60,542 | 43,627 |
| Supplemental Information | – | – | – | – |
| Interest Income | $41,943 | $27,620 | $8,713 | $466 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2,560 | $3,541 | $1,405 | $906 |
| EBITDA | -$235,859 | -$210,513 | -$127,738 | -$78,087 |
| % Margin | – | – | -1,354% | -423.5% |